Lilly Q3 revenue up 37% to $9.5B; reported EPS loss $0.06 on $3.29 IPR&D charges, non-GAAP EPS $0.10

ELI LILLY & Co

2023-Q3 EPS reported $3.38 revenue$24,770,700,000

Revenue $9,498.6M (+37% YoY) driven by Mounjaro, Verzenio, and $1.42B from olanzapine rights sale.
Reported net loss of $57.4M ($0.06 loss per share); non-GAAP net income $94.8M ($0.10 EPS).
Acquired IPR&D charges of $3.29/share and olanzapine gain of $1.22/share impacted EPS.
2023 reported EPS guidance lowered to $5.95-$6.15; non-GAAP EPS to $6.50-$6.70.
Completed acquisitions of DICE, Versanis, Emergence, Sigilon; agreed to buy POINT Biopharma.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

ELI LILLY & Co reported the third quarter of 2023 results: revenue $9,498.6, net income $(57.4), EPS $(0.06).

Period: the third quarter of 2023
Revenue: $9,498.6
Net income: $(57.4)
EPS: $(0.06)
Result: reported results

Exact text from the filing

Revenue $9,498.6 $6,941.6 37% Net income (loss) – Reported (57.4) 1,451.7 NM Earnings (loss) per share – Reported (0.06) 1.61 NM

View on SEC.gov

Browse all earnings releases →

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-23-000282

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.